Intra-lesional interleukin-2 therapy for in transit melanoma

Journal of Surgical Oncology

Volumn 109, Issue 4, 2014, Pages 327-331

  Temple Oberle, Claire F ^a   Byers, Brett A ^a   Hurdle, Valerie ^a   Fyfe, Allison ^b   McKinnon, J Gregory ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

Author keywords

in transit melanoma; interleukin 2; intra lesional; melanoma

Indexed keywords

IN-TRANSIT MELANOMA; INTERLEUKIN-2; INTRA-LESIONAL; MELANOMA;

HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MELANOMA; NEOPLASM METASTASIS;

EID: 84893913688     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23556     Document Type: Review

References (43)

1. Pawlik TM, Ross MI, Johnson MM, et al.: Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005; 12: 587-596.
2. Balch CM, Gershenwald JE, Soong SJ, et al.: Final version of the 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
3. Huffman TA, Sterin WK:, Ten-year survival with multiple metastatic malignant melanoma. Primary site unknown. Arch Surg 1973; 106: 234-235.
4. Strauss A, et al.: Radiation therapy of malignant melanomas: An evaluation of clinically used fractionation schemes. Cancer 1981; 47: 1262-1266.
5. Atallah E, Flaherty L:, Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005; 6: 185-193.
6. Tarhini AA, Agarwala SS:, Interleukin-2 for the treatment of melanoma. Curr Opin Investig Drugs 2005; 6: 1234-1239.
7. Eklund JW, Kuzel TM:, A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 2004; 16: 542-546.
8. Thompson JF, Kam PC, Waugh RC, et al.: Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14: 238-247.
9. Brady MS, Brown K, Patel A, et al.: A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006; 13: 1123-1129.
10. Beasley GM, Petersen RP, Yoo J, et al.: Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008; 5: 2195-2205.
11. Fraker DL:, Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr Treat Options Oncol 2004; 5: 173-184.
12. Koops HS, Vaglini M, Suciu S, et al.: Prophylactic isolated limb perfusion for localized, highrisk limb melanoma: Results of a multicenter randomized phase III trial. J Clin Oncol 1998; 16: 2906-2912.
13. Krementz ET, Sutherland CM, Muchmore JH:, Isolated hyperthermia chemotherapy perfusion for limb melanoma. Surg Clin North Am 1996; 76: 1313-1330.
14. Bonifati DM, Ori C, Rossi CR, et al.: Neuromuscular damage after hyperthermic isolated limb perfusion with melanoma or sarcoma treated with chemotherapeutic agents. Cancer Chemother Pharmacol 2000; 46: 517-522.
15. Vrouenraets BC, Kroon BB, Klaase JM, et al.: Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res 1995; 5: 425-431.
16. Noorda EM, van Kreij RH, Vrouenraets BC, et al.: The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. Eur J Surg Oncol 2007; 33: 776-782.
17. Radny P, Caroli UM, Bauer J, et al.: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastasis. Br J Cancer 2003; 89: 1620-1626.
18. Ridolfi L, Ridolfi R:, Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepato-Gastroenterology 2002; 49: 335-339.
19. Dehesa LA, et al.: Experience in the treatment of cutaneous in transit melanoma metastases and satellitosis with intralesional interleukin-2. Actas Dermosifiliogr 2009; 100: 571-585.
20. Weide B, Derhovanessian E, Pflugfelder A, et al.: High response rate after intratumoral treatment with interleukin-2: Results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 2010; 116: 4139-4146.
21. Green DS, Bodman-Smith MD, Dalgleish AG, et al.: Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007; 156: 337-345.
22. Boyd KU, Wehrli BM, Temple CL:, Intra-lesional interleukin-2 for the treatment of in transit melanoma. J Surg Oncol 2011; 104: 711-717.
23. Smith KA:, Interleukin-2: Inception, impact, and implications. Science 1988; 240: 1169-1176.
24. Sompayrac L:, How the immune system works, 3rd edition. Chinchester, West Sussex: Blackwell Publishing; 2008; 21-22, 128-129.
25. Morgan DA, Ruscett FW, Gallo R:, Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007-1008.
26. Nelson BH, Willerford DM:, Biology of the interleukin-2 receptor. Adv Immunol 1998; 70: 1-81.
27. Liao W, Lin JX, Leonard WJ:, Interleukin-2 at the crossroads of effector response, tolerance, and immunotherapy. Immunity 2012; 38: 13-25.
28. Cantrell DA, Smith DA, Smith KA:, The interleukin-2 T-cell system: A new cell growth model. Science 1984; 224: 1312-1314.
29. Waldman TA:, The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595-601.
30. Eklund JW, Kuzel TM:, Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma. Cancer Treat Res 2005; 126: 263-287.
31. Byers B, Temple-Oberle CF, McKinnon JG, et al.: Treatment of in transit melanoma with intra-lesional interleukin-2: A systematic review. Can J Plast Surg 2013; 21: 142.
32. Wells GA, Shea B, O'Connell D, et al.: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed June 2, 2012.
33. Personal communications with Dr. Greg McKinnon (Calgary, AB), Dr. Kelly Dabbs (Edmonton, AB), Dr. Pam Hebbard (Winnipeg, MB), Dr. Frances Wright (Toronto, ON), Dr. Elizabeth Saettler (London, ON), Joel Claveau (Quebec, QC), and Dr. Carmen Giacomantonio (Halifax, NS), 2013.
34. Chin-Lenn L, Temple-Oberle CF, McKinnon GJ:, Isolated limb infusion for melanoma in-transit metastases: Experience at two Canadian centres. Ann Surg Oncol 2013; 20: S93.
35. Kroon HM, Thompson JF:, Isolated limb infusion: A review. J Surg Oncol 2009; 100: 169-177.
36. Thompson JF, Lai DT, Ingvar C, et al.: Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994; 4S: 45-50.
37. Davis AM, Wright JG, Williams JI, et al.: Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual Life Res 1996; 5: 508-516.
38. Hudak PL, Amadio PC, Bombardier C:, Development of an upper extremity outcome measure: The DASH (disabilities of the arm, shoulder and hand). The Upper Extremity Collaborative Group (UECG). Am J Ind Med 1996; 29: 602-608.
39. Temple CLF, Ernst S, Pautler S, et al.: High-dose interleukin-2 for metastatic melanoma: Challenges and early results. Can J Plast Surg 2005; 13: 106.
40. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
41. Hoos A, Ibrahim R, Korman A, et al.: Development of ipilimumab: Contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37: 533-546.
42. Wolchok JD, Hoos A, O'Day S, et al.: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
43. Joseph RW, Sullivan RJ, Harrell R, et al.: Correlation of NRAS mutation with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 2012; 35: 66-72.